5-hydroxytryptophan has been researched along with Diabetes Mellitus, Type 2 in 3 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Demine, S | 1 |
| Schulte, ML | 1 |
| Territo, PR | 1 |
| Eizirik, DL | 1 |
| Carlbom, L | 1 |
| Espes, D | 1 |
| Lubberink, M | 1 |
| Martinell, M | 1 |
| Johansson, L | 1 |
| Ahlström, H | 1 |
| Carlsson, PO | 1 |
| Korsgren, O | 1 |
| Eriksson, O | 1 |
| Cangiano, C | 1 |
| Laviano, A | 1 |
| Del Ben, M | 1 |
| Preziosa, I | 1 |
| Angelico, F | 1 |
| Cascino, A | 1 |
| Rossi-Fanelli, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [11C]5-Hydroxy-tryptophan Positron Emission Tomography for Assessment of Islet Mass During Progression of Type 2 Diabetes[NCT02967354] | 39 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Uptake of tracer with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release (NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | % of injected dose (Mean) |
|---|---|
| Healthy Control | 0.17 |
| Obese With Oral Antidiabetic Drugs | 0.21 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 0.20 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 0.23 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 0.15 |
(NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | % of liver volume (Mean) |
|---|---|
| Healthy Control | 5.30 |
| Obese With Oral Antidiabetic Drugs | 14.40 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 13.42 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 5.50 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 9.01 |
(NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | % of pancreatic volume (Mean) |
|---|---|
| Healthy Control | 11.33 |
| Obese With Oral Antidiabetic Drugs | 11.54 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 8.75 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 9.58 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 9.72 |
Uptake of radioactive water with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release (NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | ml/min (Mean) |
|---|---|
| Healthy Control | 84.37 |
| Obese With Oral Antidiabetic Drugs | 134.90 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 107.72 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 72.20 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 59.82 |
(NCT02967354)
Timeframe: Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release
| Intervention | cm^3 (Mean) |
|---|---|
| Healthy Control | 67.68 |
| Obese With Oral Antidiabetic Drugs | 88.54 |
| Obese, Treated With Oral Antidiabetic Drugs + Insulin | 98.96 |
| Normal Weight, Treated With Oral Antidiabetic Drugs | 64.1 |
| Normal Weight, Treated With Oral Antidiabetic Drugs + Insulin | 53.39 |
1 review available for 5-hydroxytryptophan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.
Topics: 5-Hydroxytryptophan; Animals; Biomarkers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipe | 2020 |
1 trial available for 5-hydroxytryptophan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients.
Topics: 5-Hydroxytryptophan; Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; | 1998 |
1 other study available for 5-hydroxytryptophan and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
[
Topics: 5-Hydroxytryptophan; Aged; Arginine; Blood Glucose; C-Peptide; Carbon Radioisotopes; Case-Control St | 2017 |